Shareholder_NN information_NN Ownership_NN structure_NN Holdings_NNS by_IN size_NN as_IN at_IN 31_CD December_NNP 2002_CD %_NN of_IN Number_NN of_IN %_NN of_IN Number_NN of_IN ordinary_JJ Size_NN of_IN shareholding_NN holdings_NNS total_VBP holdings_NNS ordinary_JJ shares_NNS shares_NNS Over_IN 1,000,000_CD 105_CD 0.78_CD 533,599,190_CD 76.03_CD 100,001_CD 1,000,000_CD 384_CD 2.87_CD 120,864,910_CD 17.22_CD 10,001_CD 100,000_CD 901_CD 6.72_CD 29,290,396_CD 4.17_CD 5,001_CD 10,000_CD 677_CD 5.05_CD 4,704,777_CD 0.67_CD 1,001_CD 5,000_CD 4,694_CD 35.03_CD 9,882,074_CD 1.41_CD 501_CD 1,000_CD 3,333_CD 24.87_CD 2,493,286_CD 0.36_CD 1_CD 500_CD 3,307_CD 24.68_CD 977,450_CD 0.14_CD 13,401_CD 100.00_CD 701,812,083_CD 100.00_CD Directors_NNS Mr_NNP R_NNP D_NNP Lapthorne_NNP CBE_NNP Chairman_NNP ,_, Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP Mr_NNP J_NNP Fr_NNP Odfjell_NNP Deputy_NNP Chairman_NNP ,_, Chairman_NNP of_IN the_DT Nomination_NNP Committee_NNP Sir_NNP William_NNP Castell_NNP Chief_NNP Executive_NNP Mr_NNP G_NNP W_NNP Battersby_NNP Human_NNP Resources_NNP Director_NNP Mr_NNP D_NNP H_NNP Brydon_NNP OBE_NNP Non-Executive_NNP Director_NNP ,_, Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP Dr_NNP A_NNP Carr_NNP President_NNP ,_, Amersham_NNP Biosciences_NNP Mr_NNP J_NNP H_NNP Johansen_NNP Non-Executive_NNP Director_NNP ,_, employee_NN representative_NN Mr_NNP G_NNP F_NN B_NNP Kerr_NNP Finance_NNP Director_NNP Mr_NNP P_NNP Loescher_NNP President_NNP ,_, Amersham_NNP Health_NNP Dr_NNP J_NNP S_NNP Patterson_NNP Non-Executive_NNP Director_NNP Professor_NNP Sir_NNP Keith_NNP Peters_NNP Non-Executive_NNP Director_NNP Mr_NNP J_NNP F_NN Rejeange_NNP Non-Executive_NNP Director_NNP Professor_NNP E_NNP Thorsby_NNP Non-Executive_NNP Director_NNP Professor_NNP M_NNP Uhln_NNP Non-Executive_NNP Director_NNP Full_NNP details_NNS of_IN the_DT Board_NNP and_CC its_PRP$ Committees_NNS are_VBP given_VBN on_IN pages_NNS 36_CD to_TO 37_CD ._.
Secretary_NNP and_CC registered_VBN ofce_NN Sub-registrar_NN ,_, Norway_NNP Mr_NNP R_NNP E_NNP B_NNP Allnutt_NNP Den_NNP norske_NNP Bank_NNP ,_, ASA_NNP Amersham_NNP Place_NNP Registrar_NNP Department_NNP Little_NNP Chalfont_NNP Postboks_NNP 1171_CD Buckinghamshire_NNP Sentrum_NNP HP7_NNP 9NA_NNP 0107_CD Oslo_NNP Telephone_NNP 44_CD 0_CD 1494 544000_CD Norway_NNP Registered_NNP in_IN England_NNP Wales_NNP No_NNP 1002610_NNP Telephone_NNP :_: 47_CD 22_CD 48_CD 1050_CD http_NN :_: www_NN ._.
no_DT Registrar_NNP and_CC transfer_VB ofce_JJ US_NNP Depositary_NNP Lloyds_NNP TSB_NNP Registrars_NNPS Citibank_NNP N._NNP A._NNP The_NNP Causeway_NNP 111_CD Wall_NNP Street_NNP Worthing_NNP 21st_CD Floor_NNP West_NNP Sussex_NNP New_NNP York_NNP 10043_CD BN99_NNP 6DA_NNP Telephone_NNP :_: 1_CD 877 248 4237_CD Telephone_NNP 44_CD 0_CD 870 600 3998_CD 1-877-CITIADR_NN http_NN :_: www_NN ._.
com_NN adr_NN Shareholder_NN services_NNS Amersham_NNP plc_NN offer_VBP a_DT range_NN of_IN shareholder_NN services_NNS including_VBG direct_JJ payment_NN of_IN your_PRP$ dividends_NNS into_IN your_PRP$ bank_NN account_NN ,_, payment_NN of_IN dividends_NNS in_IN foreign_JJ currencies_NNS ,_, a_DT dividend_NN reinvestment_NN plan_NN ,_, a_DT corporate_JJ ISA_NNP ,_, proxy_NN voting_NN on_IN line_NN and_CC the_DT ability_NN to_TO donate_VB unwanted_JJ shares_NNS to_TO charity_NN through_IN ShareGift_NNP ._.
Please_VB see_VB enclosed_VBN information_NN leaet_NN for_IN further_JJ details_NNS or_CC call_VB 0870 600 3998_CD or_CC visit_NN www_NN ._.
Financial_NNP calendar_NN 25_CD April_NNP 2003_CD Record_NNP date_NN in_IN UK_NNP ,_, Norway_NNP and_CC USA_NNP for_IN final_JJ dividend_NN 7_CD May_NNP 2003_CD Annual_JJ General_NNP Meeting_VBG 2_CD June_NNP 2003_CD UK_NNP ,_, Norway_NNP and_CC US_NNP payment_NN of_IN final_JJ dividend_NN of_IN 5.15_CD p_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD July_NNP 2003_CD Announcement_NN of_IN results_NNS for_IN half_DT year_NN to_TO 30_CD June_NNP 2003_CD and_CC of_IN interim_JJ dividend_NN November_NNP 2003_CD Payment_NN of_IN interim_JJ dividend_NN February_NNP 2004_CD Announcement_NN of_IN results_NNS for_IN year_NN to_TO 31_CD December_NNP 2003_CD and_CC of_IN proposed_VBN final_JJ dividend_NN Amersham_NNP plc_NN 93_CD Glossary_NNP angiogenesis_NN the_DT growth_NN of_IN new_JJ blood_NN vessels_NNS supplying_VBG a_DT tumor_NN a_DT potential_JJ target_NN for_IN diagnostics_NNS and_CC therapies_NNS aimed_VBN at_IN cutting_VBG off_RP the_DT blood_NN supply_NN and_CC starving_VBG the_DT tumor_NN anti-sense_JJ drugs_NNS small_JJ molecules_NNS that_WDT interfere_VBP with_IN the_DT process_NN of_IN protein_NN production_NN ._.
They_PRP are_VBP designed_VBN to_TO bind_NN to_TO a_DT specic_JJ region_NN of_IN the_DT target_NN messenger_NN RNA_NNP ,_, thus_RB preventing_VBG the_DT production_NN of_IN the_DT protein_NN molecule_NN bioassay_NN a_DT biological_JJ test_NN or_CC analysis_NN ,_, used_VBN in_IN high_JJ throughput_NN screening_VBG to_TO test_VB the_DT effect_NN of_IN potential_JJ drug_NN compounds_NNS on_IN target_NN molecules_NNS implicated_VBN in_IN disease_NN ,_, and_CC to_TO identify_VB validate_JJ lead_NN compounds_NNS biopharmaceutical_VBP a_DT drug_NN eg_NN ._.
insulin_NN based_VBN upon_IN biological_JJ molecules_NNS such_JJ as_IN proteins_NNS ,_, which_WDT are_VBP produced_VBN in_IN cell_NN culture_NN and_CC subsequently_RB separated_VBD and_CC puried_VBD through_IN chromatographic_JJ and_CC ltration_NN techniques_NNS bioprocess_NN chromatography_NN separations_NNS media_NNS and_CC systems_NNS for_IN purifying_VBG proteins_NNS a_DT necessary_JJ step_NN in_IN the_DT manufacture_NN of_IN biopharmaceuticals_NNS brachytherapy_JJ treatment_NN of_IN cancers_NNS by_IN close_JJ range_NN radiation_NN ,_, eg_NN ._.
through_IN radioactive_JJ implants_NNS chromatography_VBP a_DT technique_NN used_VBN to_TO analyze_VB or_CC separate_JJ molecules_NNS ,_, such_JJ as_IN proteins_NNS and_CC DNA_NNP coronary_JJ angiography_NN a_DT scanning_VBG procedure_NN for_IN visualising_VBG the_DT arteries_NNS that_WDT supply_VBP the_DT heart_NN with_IN blood_NN CT_NNP computed_VBD tomography_NN an_DT X-ray_NN technique_NN that_WDT provides_VBZ computer-generated_JJ sliced_JJ images_NNS of_IN the_DT body_NN cyclotron_NN machine_NN in_IN which_WDT positively_RB charged_VBD particles_NNS are_VBP accelerated_VBN in_IN a_DT spiral_NN path_NN in_IN a_DT vacuum_NN between_IN poles_NNS of_IN a_DT magnet_NN ,_, energy_NN being_VBG provided_VBN by_IN a_DT high_JJ frequency_NN voltage_NN across_IN the_DT vacuum_NN used_VBN to_TO produce_VB radioisotopes_NNS for_IN medical_JJ purposes_NNS 2D_VBP DIGE_NNP two-dimensional_JJ uorescence_NN difference_NN in-gel_JJ electrophoresis_NN ,_, a_DT proteomics_NNS research_NN technology_NN for_IN comparison_NN of_IN protein_NN expression_NN samples_NNS from_IN normal_JJ and_CC diseased_JJ tissues_NNS ,_, and_CC monitoring_VBG the_DT effect_NN of_IN drugs_NNS on_IN the_DT tissues_NNS DNA_NNP the_DT genetic_JJ material_NN of_IN most_JJS living_VBG organisms_NNS ,_, which_WDT contains_VBZ heritable_JJ characteristics_NNS packaged_VBN deoxyribonucleic_JJ acid_NN in_IN genes_NNS electrophoresis_NN separation_NN technique_NN based_VBN on_IN the_DT movement_NN of_IN suspended_VBN particles_NNS through_IN a_DT uid_NN under_IN the_DT action_NN of_IN an_DT electric_JJ eld_NN EMEA_NNP European_NNP Medicines_NNP Evaluation_NNP Agency_NNP ,_, the_DT regulatory_JJ authority_NN in_IN the_DT European_NNP Union_NNP endocardial_JJ border_NN visualisation_NN of_IN the_DT surface_NN of_IN the_DT heart_NN muscle_NN ,_, for_IN improved_VBN assessment_NN of_IN heart_NN wall_NN motion_NN delineation_NN in_IN ultrasound_NN imaging_NN enzymes_VBZ any_DT of_IN numerous_JJ complex_JJ protein_NN substances_NNS that_WDT are_VBP produced_VBN by_IN living_VBG cells_NNS and_CC bring_VB about_RB or_CC accelerate_VB reactions_NNS :_: enzymology_NN ,_, the_DT study_NN of_IN enzymes_NNS ,_, their_PRP$ nature_NN ,_, activity_NN and_CC signicance_NN external_JJ beam_NN radiation_NN treatment_NN of_IN cancer_NN by_IN irradiating_VBG the_DT tumor_NN from_IN a_DT source_NN outside_IN the_DT body_NN FDA_NNP Food_NNP and_CC Drug_NNP Administration_NNP ,_, the_DT regulatory_JJ authority_NN in_IN the_DT United_NNP States_NNPS FDG_NNP uoro-deoxyglucose_NN a_DT sugar_NN molecule_NN labeled_VBN with_IN the_DT radioisotope_NN uorine-18_NN ,_, a_DT highly_RB sensitive_JJ molecular_JJ diagnostic_JJ used_VBN in_IN PET_NNP imaging_NN gamma_NN camera_NN a_DT scanning_VBG instrument_NN that_IN detects_VBZ gamma_NN rays_NNS emitted_VBN by_IN radiopharmaceuticals_NNS ,_, enabling_VBG the_DT visualisation_NN of_IN organ_NN function_NN :_: see_VB SPECT_NNP genomics_NNS the_DT study_NN of_IN the_DT genetic_JJ material_NN on_IN an_DT organism-wide_JJ basis_NN eg_NN ._.
the_DT human_JJ genome_NN is_VBZ the_DT set_NN of_IN genes_NNS that_WDT code_VBP for_IN a_DT human_JJ being_NN ._.
Genomics_NNS includes_VBZ the_DT analysis_NN of_IN gene_NN function_NN ,_, gene_NN expression_NN see_VBP microarray_NN and_CC genetic_JJ variation_NN see_VBP SNP_NNP high_JJ throughput_NN screening_VBG simultaneous_JJ screening_NN of_IN large_JJ numbers_NNS of_IN drug_NN candidates_NNS against_IN protein_NN molecules_NNS implicated_VBN in_IN disease_NN informatics_NNS the_DT use_NN of_IN powerful_JJ computer_NN technology_NN software_NN and_CC data_NNS management_NN systems_NNS for_IN the_DT collection_NN ,_, storage_NN ,_, analysis_NN and_CC organization_NN of_IN very_RB large_JJ amounts_NNS of_IN biological_JJ data_NNS 94_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD interferons_NNS a_DT group_NN of_IN proteins_NNS produced_VBD naturally_RB by_IN the_DT cells_NNS of_IN our_PRP$ bodies_NNS ,_, which_WDT increase_VBP the_DT resistance_NN of_IN cells_NNS to_TO viral_JJ infection_NN in_IN vitro_NN biological_JJ processes_NNS observed_VBD outside_IN the_DT body_NN ,_, eg_NN ._.
in_IN a_DT test_NN tube_NN in_IN vivo_NN biological_JJ processes_NNS observed_VBD in_IN a_DT living_NN organism_NN left_VBD ventricular_JJ function_NN how_WRB well_RB the_DT left_VBN ventricle_NN of_IN the_DT heart_NN is_VBZ doing_VBG its_PRP$ job_NN of_IN pumping_VBG blood_NN into_IN the_DT aorta_NN ,_, the_DT great_JJ trunk_NN artery_NN that_WDT carries_VBZ blood_NN from_IN the_DT heart_NN through_IN the_DT body_NN mass_NN spectrometry_NN analysis_NN instrument_NN based_VBN on_IN the_DT mass-to-charge_NN ratio_NN of_IN a_DT substance_NN metastasis_NN spreading_VBG of_IN cancer_NN from_IN the_DT primary_JJ tumor_NN to_TO other_JJ sites_NNS in_IN the_DT body_NN microarray_NN a_DT system_NN consisting_VBG of_IN thousands_NNS of_IN minute_NN samples_NNS of_IN genetic_JJ material_NN deposited_VBD or_CC synthesised_VBD on_IN slides_NNS or_CC biochips_NNS ,_, for_IN rapid_JJ identication_NN and_CC analysis_NN of_IN gene_NN expression_NN i._FW e._FW which_WDT genes_NNS are_VBP expressed_VBN or_CC active_JJ in_IN normal_JJ and_CC diseased_JJ tissue_NN ,_, or_CC in_IN response_NN to_TO drug_NN treatment_NN monoclonal_JJ antibody_NN an_DT antibody_NN produced_VBN by_IN a_DT single_JJ type_NN of_IN immune_JJ cell_NN which_WDT binds_VBZ to_TO a_DT specic_JJ part_NN of_IN its_PRP$ protein_NN target_NN MRI_NNP magnetic_JJ an_DT imaging_NN technology_NN using_VBG radio_NN waves_NNS and_CC a_DT magnetic_JJ eld_NN to_TO produce_VB high_JJ resolution_NN images_NNS resonance_NN imaging_NN of_IN slices_NNS through_IN the_DT body_NN myocardium_NN the_DT middle_JJ muscular_JJ layer_NN of_IN the_DT heart_NN wall_NN myocardial_JJ infarction_NN a_DT term_NN used_VBN to_TO describe_VB irreversible_JJ injury_NN to_TO heart_NN muscle_NN neurology_NN the_DT study_NN of_IN the_DT nervous_JJ system_NN brain_NN ,_, spinal_JJ cord_NN and_CC nerves_NNS non-Hodgkins_JJ lymphoma_NN a_DT heterogeneous_JJ group_NN of_IN malignant_JJ cancers_NNS of_IN the_DT lymphatic_JJ system_NN non-ionic_JJ in_IN contrast_NN media_NNS ,_, a_DT compound_NN which_WDT does_VBZ not_RB dissociate_VB in_IN solution_NN and_CC therefore_RB has_VBZ a_DT low_JJ osmolality_NN number_NN of_IN particles_NNS in_IN a_DT given_VBN volume_NN of_IN liquid_NN ._.
This_DT reduces_VBZ side_NN effects_NNS and_CC discomfort_NN upon_IN injection_NN ,_, particularly_RB for_IN X-ray_NN contrast_NN media_NNS ._.
nucleotide_IN the_DT building_NN block_NN of_IN DNA_NNP and_CC RNA_NNP oncology_VBP the_DT study_NN of_IN tumors_NNS :_: cancer_NN peptide_NN a_DT short_JJ sequence_NN of_IN amino_JJ acids_NNS forming_VBG part_NN of_IN a_DT protein_NN perfusion_NN cardiac_JJ how_WRB well_RB the_DT heart_NN is_VBZ being_VBG supplied_VBN with_IN blood_NN PET_NNP positron-emission_NN a_DT highly_RB sensitive_JJ radiopharmaceutical_JJ imaging_NN technique_NN eg_NN ._.
for_IN cancer_NN ,_, where_WRB PET_NNP can_MD detect_VB tomography_NN very_RB early_RB signs_NNS of_IN the_DT cancer_NN spreading_VBG pharmacological_JJ drugs_NNS administered_VBN to_TO make_VB the_DT heart_NN work_NN harder_RB ,_, used_VBN for_IN testing_NN heart_NN function_NN in_IN patients_NNS stress_NN agents_NNS who_WP are_VBP unable_JJ to_TO exercise_VB on_IN a_DT treadmill_NN preclinical_JJ studies_NNS of_IN a_DT potential_JJ new_JJ drug_NN to_TO determine_VB its_PRP$ safety_NN ,_, metabolic_JJ properties_NNS and_CC effectiveness_NN before_IN it_PRP can_MD be_VB administered_VBN to_TO patients_NNS in_IN clinical_JJ trials_NNS protein_NN one_CD of_IN the_DT myriad_JJ of_IN complex_JJ molecules_NNS that_WDT control_VBP all_DT cellular_JJ functions_NNS and_CC are_VBP coded_VBN for_IN by_IN genes_NNS proteome_VBP all_PDT the_DT proteins_NNS produced_VBD from_IN all_DT the_DT genes_NNS of_IN a_DT genome_NN proteomics_NNS the_DT study_NN of_IN specic_JJ proteins_NNS expressed_VBN in_IN cells_NNS and_CC tissues_NNS ,_, with_IN the_DT aim_NN of_IN determining_VBG their_PRP$ function_NN and_CC their_PRP$ role_NN in_IN disease_NN ,_, and_CC identifying_VBG potential_JJ new_JJ drug_NN targets_NNS pulmonary_JJ embolism_NN the_DT sudden_JJ obstruction_NN of_IN a_DT blood_NN vessel_NN in_IN the_DT lung_NN by_IN a_DT blood_NN clot_NN that_WDT has_VBZ circulated_VBN in_IN the_DT blood_NN and_CC lodged_VBN in_IN the_DT lungs_NNS radioisotope_VBP a_DT radioactive_JJ form_NN of_IN a_DT chemical_NN element_NN Amersham_NNP plc_NN 95_CD Glossary_NNP continued_VBD radioimmunotherapy_JJ a_DT cancer_NN treatment_NN that_WDT uses_VBZ immune_JJ system_NN antibodies_NNS to_TO carry_VB cancer-killing_JJ radioactive_JJ agents_NNS directly_RB to_TO tumor_NN cells_NNS radiopharmaceutical_JJ radioactively-tagged_JJ compound_NN necessary_JJ to_TO produce_VB a_DT nuclear_JJ medicine_NN image_NN ,_, also_RB called_VBD a_DT tracer_NN or_CC radionuclide_NN renal_JJ relating_VBG to_TO the_DT kidneys_NNS RNA_NNP ribonucleic_JJ acid_NN a_DT chemical_NN found_VBN in_IN the_DT nucleus_NN and_CC cytoplasm_NN of_IN cells_NNS ,_, which_WDT plays_VBZ an_DT important_JJ role_NN in_IN protein_NN synthesis_NN and_CC other_JJ chemical_NN activities_NNS of_IN the_DT cell_NN ._.
The_DT structure_NN of_IN RNA_NNP is_VBZ similar_JJ to_TO that_DT of_IN DNA_NNP ._.
There_EX are_VBP several_JJ classes_NNS of_IN RNA_NNP molecules_NNS :_: messenger_NN RNA_NNP ,_, transfer_NN RNA_NNP ,_, and_CC ribosomal_JJ RNA_NNP ._.
sequencing_VBG identifying_VBG the_DT order_NN of_IN the_DT letters_NNS nucleotides_NNS in_IN the_DT DNA_NNP code_NN SNP_NNP single_JJ nucleotide_NN very_RB small_JJ genetic_JJ differences_NNS between_IN individuals_NNS ,_, which_WDT may_MD affect_VB disease_NN susceptibility_NN and_CC polymorphisms_NNS response_NN to_TO drugs_NNS SPECT_NNP single_JJ photon_NN a_DT functional_JJ imaging_NN technique_NN producing_VBG computer-generated_JJ sliced_JJ images_NNS of_IN the_DT body_NN based_VBN emission_NN computed_VBN on_IN the_DT detection_NN of_IN gamma_NN rays_NNS photons_NNS emitted_VBN by_IN radiopharmaceuticals_NNS tomography_JJ stenosis_NN narrowing_NN of_IN the_DT blood_NN vessels_NNS ._.
Restenosis_NNP is_VBZ the_DT re-narrowing_NN of_IN the_DT blood_NN vessels_NNS after_IN initial_JJ treatment_NN of_IN coronary_JJ artery_NN disease_NN stent_VBD a_DT small_JJ tube_NN inserted_VBN into_IN a_DT blood_NN vessel_NN to_TO prevent_VB restenosis_NN thrombus_NN a_DT blood_NN clot_NN formed_VBD within_IN a_DT blood_NN vessel_NN and_CC remaining_VBG attached_VBN to_TO its_PRP$ point_NN of_IN origin_NN toxicology_NN the_DT study_NN of_IN the_DT effect_NN of_IN foreign_JJ substances_NNS on_IN the_DT body_NN and_CC its_PRP$ functioning_VBG vascular_JJ relating_VBG to_TO the_DT blood_NN vessels_NNS ,_, as_IN of_IN the_DT heart_NN cardiovascular_JJ or_CC brain_NN cerebrovascular_JJ 96_CD Amersham_NNP plc_NN Annual_JJ Report_NNP &_CC Accounts_NNPS 2002_CD Cautionary_JJ statement_NN for_IN purposes_NNS of_IN the_DT safe_JJ harbor_NN provisions_NNS of_IN the_DT United_NNP States_NNP Private_NNP Securities_NNP Litigation_NNP Reform_NNP Act_NNP of_IN 1995_CD ._.
The_DT Private_JJ Securities_NNPS Litigation_NNP Reform_NNP Act_NNP of_IN 1995_CD provides_VBZ for_IN a_DT safe_JJ harbor_NN for_IN forward-looking_JJ statements_NNS ._.
This_DT Annual_JJ Report_NNP contains_VBZ words_NNS such_JJ as_IN believe_VBP ,_, expect_VBP and_CC anticipate_VBP and_CC similar_JJ expressions_NNS ,_, that_IN identify_VB forward-looking_JJ statements_NNS ,_, which_WDT reflect_VBP the_DT groups_NNS views_NNS about_IN future_JJ events_NNS and_CC financial_JJ performance_NN ._.
Such_JJ forward-looking_JJ statements_NNS relate_VBP to_TO the_DT outlook_NN of_IN Amersham_NNP plc_NN ,_, including_VBG in_IN particular_JJ ,_, the_DT expected_VBN growth_NN of_IN certain_JJ of_IN the_DT groups_NNS products_NNS or_CC the_DT markets_NNS for_IN those_DT products_NNS and_CC the_DT impact_NN of_IN currency_NN movements_NNS during_IN 2003_CD ._.
Actual_JJ results_NNS could_MD differ_VB materially_RB from_IN those_DT projected_VBN in_IN such_JJ forward_RB looking_VBG statements_NNS as_IN a_DT result_NN of_IN various_JJ factors_NNS that_WDT may_MD be_VB beyond_IN the_DT control_NN of_IN the_DT group_NN ._.
The_DT following_VBG important_JJ factors_NNS could_MD cause_VB actual_JJ results_NNS to_TO differ_VB materially_RB from_IN those_DT projected_VBN or_CC implied_VBN in_IN any_DT forwardlooking_VBG statements_NNS :_: i_FW changes_NNS in_IN demand_NN for_IN the_DT products_NNS of_IN Amersham_NNP plc_NN worldwide_NN or_CC the_DT markets_NNS for_IN those_DT products_NNS as_RB well_RB as_IN changes_NNS in_IN managements_NNS expectation_NN of_IN the_DT development_NN of_IN new_JJ markets_NNS and_CC the_DT timing_NN of_IN completion_NN of_IN various_JJ trials_NNS leading_VBG to_TO the_DT introduction_NN of_IN new_JJ products_NNS :_: ii_FW changes_NNS in_IN the_DT cost_NN or_CC supply_NN of_IN raw_JJ materials_NNS ,_, changes_NNS in_IN interest_NN rates_NNS and_CC the_DT impact_NN of_IN competition_NN :_: iii_FW price_NN controls_NNS and_CC price_NN reductions_NNS ,_, fluctuations_NNS in_IN exchange_NN rates_NNS for_IN foreign_JJ currencies_NNS ,_, changes_NNS in_IN governmental_JJ regulation_NN ,_, and_CC the_DT risk_NN of_IN loss_NN of_IN patents_NNS or_CC trademarks_NNS ._.
Accordingly_RB ,_, readers_NNS are_VBP cautioned_VBN not_RB to_TO place_VB undue_JJ reliance_NN on_IN these_DT forward-looking_JJ statements_NNS ._.
In_IN any_DT event_NN ,_, these_DT statements_NNS speak_VBP only_RB as_IN of_IN the_DT date_NN on_IN which_WDT they_PRP are_VBP made_VBN ,_, and_CC the_DT group_NN does_VBZ not_RB undertake_VB any_DT obligation_NN to_TO update_VB or_CC revise_VB any_DT of_IN them_PRP ,_, whether_IN as_IN a_DT result_NN of_IN new_JJ information_NN ,_, future_JJ events_NNS or_CC otherwise_RB ._.
Amersham_NNP ,_, Amersham_NNP Health_NNP ,_, Amersham_NNP Biosciences_NNP ,_, KTA_NNP ,_, KTApilot_NNP ,_, Chromaflow_NNP ,_, CodeLink_NNP ,_, CyDye_NNP ,_, DaTSCAN_NNP ,_, EchoSeed_NNP ,_, Ettan_NNP ,_, GenomiPhi_NNP ,_, Helispin_NNP ,_, Imanet_NNP ,_, LEADseeker_NNP ,_, Ludicea_NNP ,_, MegaBACE_NNP ,_, MabSelect_NNP ,_, Myoview_NNP ,_, OligoProcess_NNP ,_, Omnipaque_NNP ,_, Omniscan_NNP ,_, OncoSeed_NNP ,_, Optison_NNP ,_, Rapid_NNP Strand_NNP ,_, Scierra_NNP ,_, Sepharose_NNP ,_, Sonazoid_NNP ,_, Source_NNP ,_, Spin_NNP Signal_NNP ,_, Streamline_NNP ,_, TempliPhi_NNP and_CC Visipaque_NNP are_VBP trademarks_NNS of_IN Amersham_NNP plc_NN TheraSeed_NNP is_VBZ a_DT trademark_NN of_IN Theragenics_NNP Corp_NNP Amersham_NNP plc_NN 2003_CD All_DT rights_NNS reserved_VBN All_DT goods_NNS and_CC services_NNS are_VBP sold_VBN subject_JJ to_TO the_DT terms_NNS and_CC conditions_NNS of_IN sale_NN of_IN the_DT company_NN within_IN the_DT Amersham_NNP group_NN which_WDT supplies_VBZ them_PRP ._.
A_DT copy_NN of_IN these_DT terms_NNS and_CC conditions_NNS is_VBZ available_JJ on_IN request_NN ._.
Amersham_NNP plc_NN ,_, Amersham_NNP Place_NNP ,_, Little_NNP Chalfont_NNP ,_, Buckinghamshire_NNP ,_, England_NNP HP7_NNP 9NA_NNP Mega_JJ Matt_NNP is_VBZ made_VBN from_IN 50_CD %_NN TCF_NNP and_CC 50_CD %_NN recycled_JJ fiber_NN in_IN accordance_NN with_IN the_DT Nordic_NNP Swan_NN Environmental_NNP Standard_NNP ._.
Designed_VBN by_IN Merchant_NN with_IN navyblue_JJ Typeset_NNP by_IN Saffron_NNP Digital_NNP Production_NNP Printed_NNP by_IN St_NNP Ives_NNP Westerham_NNP Press_NNP Amersham_NNP plc_NN Amersham_NNP Place_NNP Little_NNP Chalfont_NNP Buckinghamshire_NNP HP7_NNP 9NA_NNP England_NNP www_NN ._.
com_NN Registered_NNP in_IN England_NNP and_CC Wales_NNP 1002610_CD
